| 0.1695 -0.009 (-4.94%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.24 | 1-year : | 0.31 |
| Resists | First : | 0.2 | Second : | 0.26 |
| Pivot price | 0.16  |
|||
| Supports | First : | 0.11 | Second : | 0.09 |
| MAs | MA(5) : | 0.19 |
MA(20) : | 0.16 |
| MA(100) : | 0.27 |
MA(250) : | 1.61 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 45.9 |
D(3) : | 55.9 |
| RSI | RSI(14): 48.4 |
|||
| 52-week | High : | 3.86 | Low : | 0.11 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GOSS ] has closed below upper band by 44.6%. Bollinger Bands are 50.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 96 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.18 - 0.18 | 0.18 - 0.18 |
| Low: | 0.16 - 0.16 | 0.16 - 0.17 |
| Close: | 0.17 - 0.17 | 0.17 - 0.17 |
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Fri, 31 Jul 2026
Gossamer Bio (GOSS) Could Be 96% Undervalued After Its Seralutinib NDA Update - finance.yahoo.com
Fri, 31 Jul 2026
Bronstein, Gewirtz & Grossman, LLC Is Investigating Gossamer Bio, Inc. (GOSS) And Encourages Investors to Connect - The National Law Review
Thu, 30 Jul 2026
Gossamer Bio (GOSS) Stock Forecast & Analyst Ratings - Moomoo
Wed, 29 Jul 2026
BlackRock (GOSS) discloses 4.89M-share, 1% beneficial stake in Gossamer Bio - Stock Titan
Tue, 28 Jul 2026
Gossamer Bio Inc (GOSS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Tue, 28 Jul 2026
Gossamer Bio (NASDAQ:GOSS) Shares Surge as FDA Progress Highlights Path Forward; Cash Covenant Looms as Next Hurdle - TechStock²
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 489 (M) |
| Shares Float | 138 (M) |
| Held by Insiders | 1.5 (%) |
| Held by Institutions | 69.5 (%) |
| Shares Short | 73,180 (K) |
| Shares Short P.Month | 56,210 (K) |
| EPS | -0.8 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.69 |
| Profit Margin | 0 % |
| Operating Margin | -264.7 % |
| Return on Assets (ttm) | -52.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 71.5 % |
| Gross Profit (p.s.) | 0.11 |
| Sales Per Share | 0.11 |
| EBITDA (p.s.) | -0.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -170 (M) |
| Levered Free Cash Flow | -97 (M) |
| PE Ratio | -0.22 |
| PEG Ratio | 0 |
| Price to Book value | -0.25 |
| Price to Sales | 1.49 |
| Price to Cash Flow | -0.49 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|